These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33804441)

  • 21. Addition of the C-terminus of CD6 to a chimeric antigen receptor enhances cytotoxicity and does not compromise expression.
    Breuning J; Philip B; Brown MH
    Immunology; 2019 Feb; 156(2):130-135. PubMed ID: 30300924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 24. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
    Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
    Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
    Chmielewski M; Hombach AA; Abken H
    Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity.
    Helsen CW; Hammill JA; Lau VWC; Mwawasi KA; Afsahi A; Bezverbnaya K; Newhook L; Hayes DL; Aarts C; Bojovic B; Denisova GF; Kwiecien JM; Brain I; Derocher H; Milne K; Nelson BH; Bramson JL
    Nat Commun; 2018 Aug; 9(1):3049. PubMed ID: 30076299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
    Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain.
    Liang X; Huang Y; Li D; Yang X; Jiang L; Zhou W; Su J; Chen N; Wang W
    Gene Ther; 2023 May; 30(5):411-420. PubMed ID: 33953316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.
    Fisher J; Sharma R; Don DW; Barisa M; Hurtado MO; Abramowski P; Porter L; Day W; Borea R; Inglott S; Anderson J; Pe'er D
    Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.
    Dawson NAJ; Rosado-Sánchez I; Novakovsky GE; Fung VCW; Huang Q; McIver E; Sun G; Gillies J; Speck M; Orban PC; Mojibian M; Levings MK
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32817364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
    Li X; Daniyan AF; Lopez AV; Purdon TJ; Brentjens RJ
    Leukemia; 2021 Feb; 35(2):506-521. PubMed ID: 32447345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
    Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
    J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs.
    Balagopalan L; Moreno T; Qin H; Angeles BC; Kondo T; Yi J; McIntire KM; Alvinez N; Pallikkuth S; Lee ME; Yamane H; Tran AD; Youkharibache P; Cachau RE; Taylor N; Samelson LE
    Sci Signal; 2024 Jul; 17(846):eadp8569. PubMed ID: 39042728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The making and function of CAR cells.
    Zabel M; Tauber PA; Pickl WF
    Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model.
    Festag MM; Festag J; Fräßle SP; Asen T; Sacherl J; Schreiber S; Mück-Häusl MA; Busch DH; Wisskirchen K; Protzer U
    Mol Ther; 2019 May; 27(5):947-959. PubMed ID: 30852138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
    Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
    Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.